1-20 of 1187 Search Results for

glp-glucagon-like-peptide

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal: Diabetes
Diabetes 2004;53(9):2492–2500
Published: 01 September 2004
... activities encompassed by the native peptide remains to be demonstrated. We report that Albugon, a human glucagon-like peptide (GLP)-1–albumin recombinant protein, activates GLP-1 receptor (GLP-1R)-dependent cAMP formation in BHK-GLP-1R cells, albeit with a reduced half-maximal concentration (EC50...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1108-P
Published: 01 July 2018
...MUNIZA M. SATTI; TIMOTHY O'BRIEN; AARON LIEW Combination therapy with Glucagon-like peptide-1 receptor agonist (GLP-1RA) and basal insulin represents a new therapeutic option for diabetes mellitus. We hypothesized that GLP-1RA plus basal insulin is more efficacious, safer and tolerable than GLP-1RA...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1883-P
Published: 01 June 2019
...RHIANNA C. LAKER; MICHELLE BOLAND; ARKADIUSZ NAWROCKI; KARLY M. MATHER; LUTZ JERMUTUS; MARTIN R. LARSEN; JAMES TREVASKIS; CHRISTOPHER J. RHODES MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1/glucagon receptor activity that is in clinical development for type 2 diabetes (T2DM), NASH...
Meeting Abstracts
Journal: Diabetes
Diabetes 1998;47(4):632–639
Published: 01 April 1998
...L A Scrocchi; B A Marshall; S M Cook; P L Brubaker; D J Drucker Glucagon-like peptide-1 (GLP-1) acts to control blood glucose via multiple mechanisms, including regulation of insulin and glucagon secretion, gastric emptying, satiety, and peripheral insulin sensitivity. However, the relative...
Meeting Abstracts
Journal: Diabetes
Diabetes 2021;70(Supplement_1):995-P
Published: 01 June 2021
...SHIAU C. CHONG; NORLELA SUKOR; SARAH ROBERT; KIM F. NG; NOR A. KAMARUDDIN Introduction: IRS is a precursor to the development of prediabetes which manifests itself in the form of compensatory insulin secretion. The role of GLP-1 in this compensatory mechanism has not been well studied...
Meeting Abstracts
Journal: Diabetes
Diabetes 2021;70(Supplement_1):1093-P
Published: 01 June 2021
...JING LUO; ROBERT FELDMAN; SCOTT D. ROTHENBERGER; MICHAEL FISCHER; MARY T. KORYTKOWSKI; WALID F. GELLAD Background: The incidence and predictors of primary nonadherence (when a medication is prescribed but not dispensed) for newer glucose lowering medications including SGLT2i and GLP-1a is not known...
Meeting Abstracts
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1909-P
Published: 01 June 2020
...ALI ASMAR; PER K. CRAMON; MEENA ASMAR; LENE SIMONSEN; STEN MADSBAD; CHARLOTTE M. SORENSEN; BOLETTE HARTMANN; JENS J. HOLST; PETER HOVIND; BOYE L. JENSEN; JENS BÜLOW We have recently demonstrated that renal extraction of GLP-1 is ∼45% and that extracellular fluid volume expansion in healthy...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1010-P
Published: 01 June 2019
...VICTORIA E. PARKER; DARREN ROBERTSON; TAO WANG; DAVID C. HORNIGOLD; MAXIMILIAN G. POSCH; LEONA PLUM-MOERSCHEL; JURIS J. MEIER; HEIKE SCHLICHTHAAR; BEATE M. KLAUS; LUTZ JERMUTUS; PHILIP AMBERY; BOAZ HIRSHBERG Background: MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1/glucagon receptor...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1017-P
Published: 01 June 2019
...VICTORIA E.R. PARKER; DARREN ROBERTSON; TAO WANG; DAVID C. HORNIGOLD; MAXIMILIAN G. POSCH; TIM HEISE; LEONA PLUM-MOERSCHEL; JURIS J. MEIER; HEIKE SCHLICHTHAAR; BEATE M. KLAUS; PHILIP AMBERY; BOAZ HIRSHBERG Background: MEDI0382 is an oxyntomodulin-like peptide with GLP-1/glucagon receptor activity...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):988-P
Published: 01 June 2019
...DARREN ROBERTSON; VICTORIA E. PARKER; PHILIP AMBERY; MARCELLA PETRONE; TAO WANG; TIM HEISE; LEONA PLUM-MOERSCHEL; LUTZ JERMUTUS; BOAZ HIRSHBERG; JURIS J. MEIER Background: MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1/glucagon receptor activity under development for type 2 diabetes...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):989-P
Published: 01 June 2019
...DARREN ROBERTSON; MARCELLA PETRONE; LAN-FENG TSAI; ROBERT A. GASSER, JR. Background: MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1/glucagon receptor activity that is under development for type 2 diabetes mellitus. This study was conducted in subjects of Japanese and Chinese descent...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):367-OR
Published: 01 July 2018
...NASUI WANG; ALVIN WAI KIT TAN; LINDA JAHN, SR.; LEE HARTLINE; KEVIN W. AYLOR; EUGENE BARRETT; ZHENQI LIU Obesity is associated with metabolic and microvascular insulin resistance. The latter is characterized by impaired insulin-mediated microvascular recruitment. GLP-1 engenders vasodilation...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):543-P
Published: 01 July 2018
...SATOSHI FUNAKOSHI; MASATOSHI HAYASHIDA; KENJI SAWASE; JYUNICHIRO HASHIGUCHI; RICA ETOH; YUTAKA MORI; KAZUNORI UTSUNOMIYA; TAKASHI HARADA Objective: Dulaglutide (Dula) is a novel, long-acting glucagon-like peptide receptor antagonist (GLP-1RA) used in the treatment of T2D patients with or without...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1287-P
Published: 01 July 2018
...MUKUL SINGHAL; HIANGKIAT (JASON) TAN; CRAIG I. COLEMAN; WILLIAM H. HERMAN; JENNIFER CAI; MICHELLE HAN; MIKE INGHAM This study compared HbA1c control, treatment patterns, and costs in adults with T2DM initiated on CANA or a GLP-1 based on administrative claims data from the HealthCore Integrated...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1291-P
Published: 01 July 2018
... cohorts except for BL BMI (CANA: n = 213; GLP-1: n = 235). Significant differences in BW were seen in the CANA vs. GLP-1 cohort over 9 months of follow-up (Figure). CANA cohort patients were more likely to achieve WL ≥5% (HR 1.93; 95% CI: 1.40-2.66) with a significantly longer duration at WL ≥5% (133 vs...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):2231-PUB
Published: 01 July 2018
...SASAN FAZELI; NICOLE EHRHARDT Background: Despite multiple therapeutic options for people with T2DM, 48% of people do not achieve Hemoglobin A1c (HbA1c) goal. GLP-1 receptor agonists may be beneficial to patients with T2DM who are on large insulin doses and are obese. GLP-1 receptor agonists...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):100-LB
Published: 01 July 2018
...) to 7.7% (IQR 6.7-8.4). Patients with T2D on BI who added a GLP-1RA were likely to be <75 years old and had characteristics of progressed disease. Baseline A1C determined a ≥1% decline in A1C, suggesting patients on BI with high A1C would benefit from combination treatment with GLP-1RA. Disclosure...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1111-P
Published: 01 July 2018
...JULIO ROSENSTOCK; MICHAEL E. TRAUTMANN; MARCUS HOMPESCH; IN YOUNG CHOI; JAHOON KANG; KUN-HO YOON; CHRISTOPHER H. SORLI Once-weekly (QW), subcutaneous efpeglenatide (efpeg) is a long-acting GLP–1 RA in development for type 2 diabetes (T2D). In vitro studies have shown that efpeg...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1096-P
Published: 01 July 2018
...RUTH E. BROWN; ALEXANDER ABITBOL; HARPREET S. BAJAJ; HASNAIN KHANDWALA; RONALD GOLDENBERG; SUZAN ABDEL-SALAM; RONNIE ARONSON This prospective, observational cohort study evaluates patient-reported outcomes (PRO’s) in patients initiating GLP-1 RA therapy in a real-world setting. Patients with type 2...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1090-P
Published: 01 July 2018
...IN YOUNG CHOI; MI JIN MOON; MICHAEL E. TRAUTMANN; MARCUS HOMPESCH; CHRISTOPHER H. SORLI Efpeglenatide (efpeg) is a long-acting GLP-1 R agonist in development for the treatment of T2D. Efpeg’s effects on the GLP-1 R suggest that it is a superagonist: a ligand that leads to greater maximal signaling...